|
Aug 13
|
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
|
|
Aug 12
|
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
|
|
Aug 8
|
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
|
|
Aug 3
|
Ocugen Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 2
|
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
|
|
Aug 1
|
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 1
|
Ocugen: Q2 Earnings Snapshot
|
|
Aug 1
|
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
|
|
Jul 21
|
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
|
|
Jul 21
|
Ocugen doses first subject in trial of modifier gene therapy candidate
|
|
Jul 18
|
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
|
|
Jul 17
|
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
|
|
Jun 24
|
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
|
|
Jun 23
|
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
|
|
Jun 17
|
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
|
|
Jun 16
|
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
|
|
Jun 11
|
Ocugen To Present at BIO International Convention 2025
|
|
May 27
|
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
|
|
May 26
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Apr 16
|
Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?
|